March 21, 2024 01:45 PM EDT
Pharma

GSK joins Boehringer and As­traZeneca in cap­ping out-of-pock­et costs for in­halers

Katherine Lewin

News Reporter

GSK will cap out-of-pock­et costs for its in­halers at $35, mak­ing it the third ma­jor drug­mak­er to agree to lim­it pa­tients’ spend­ing amid sig­nif­i­cant US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

A service from the Financial Times